Cytisine versus varenicline for smoking cessation for Maori (the indigenous people of New Zealand) and their extended family: protocol for a randomized non-inferiority trial.

ABSTRACT:

Background and aims

Cytisine, a nicotinic acetylcholine receptor partial agonist (like varenicline) found in some plants, is a low-cost, effective smoking cessation medication that may appeal to Māori [the indigenous people of New Zealand (NZ)]. The RAUORA trial aims to determine the effectiveness, safety and cost-effectiveness of cytisine (Tabex^® ) versus varenicline (Champix^® ) for smoking cessation in Māori and the whānau (extended family) of Māori.

Design

Pragmatic, community-based, open-label randomized non-inferiority trial.

Setting

Lakes District Health Board region, NZ.

Participants

Daily smokers (n = 2140) who self-identify as Māori or whānau of Māori, and are: aged ≥ 18 years, motivated to quit smoking in the next 2 weeks, eligib

SUBMITTER: Walker N 

PROVIDER: S-EPMC6587772 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature